Author Archives: Andrea Gonzalez

Wall Street punishes Endologix as it extends FDA timeline for Nellix system

By Stacy Lawrence, Staff Writer Small cap Endologix Inc. lost about one-third of its valuation after it pushed back the U.S. regulatory timeline for its Nellix Endovascular Aneurysm Sealing System. The Irvine, Calif.-based company said that it needs to conduct…

FacebookTwitterGoogle+Share

Start up Robocath advances robotic assistance for over-radiated cardiologists

By John Brosky, Contributing Writer PARIS – Interventional cardiologists are as pleased to see the arrival of a robotic assistant as the workers at the Fukushima nuclear power plant meltdown site. A study published by the American Heart Association in…

FacebookTwitterGoogle+Share

New CE mark rules make the FDA seem user-friendly for cardiovascular devices

By John Brosky, Contributing Writer PARIS – One week before regulations governing the CE mark for medical devices formally takes the force of law, makers of cardiovascular devices have already turned their backs on Europe and are headed to the…

FacebookTwitterGoogle+Share

Novel diagnostic beats FFR vindicating Philips-Volcano IFR platform for cath labs

By John Brosky, Contributing Writer PARIS – A meta-analysis covering 4,529 patients presented at EuroPCR closed the door on a five-year argument over what diagnostic tool will be the gold standard in the catheterization lab for helping physicians decide whether…

FacebookTwitterGoogle+Share

Thermo Fisher to buy contract drug developer, manufacturer Patheon NV for $7.2B

By Stacy Lawrence, Staff Writer Thermo Fisher Scientific Inc. will acquire drug development and delivery services provider Patheon NV for $7.2 billion, including $2 billion of debt assumption. Diagnostics and laboratory-focused Thermo Fisher expects that the addition of the Durham,…

FacebookTwitterGoogle+Share

Watchman effective in stroke reduction for non-oral anticoagulation patients

By Omar Ford, Staff Writer CHICAGO – Results from the EWOLUTION registry show that Boston Scientific Corp.’s Watchman Left Atrial Appendage (LAA) Closure device was effective in stroke reduction for patients with non-valvular atrial fibrillation (AF), including those patients deemed…

FacebookTwitterGoogle+Share

Boston Scientific’s S-ICD shown to be effective long-term in a real world setting

By Omar Ford, Staff Writer CHICAGO – A post-market study of Boston Scientific Corp.’s subcutaneous ICD (S-ICD) supports long-term use of the device in patients. Michael Gold, president of the Heart Rhythm Society presented the results during a late breaking…

FacebookTwitterGoogle+Share

Med tech takes stronger foothold in AF with developed, emerging technologies

By Omar Ford, Staff Writer CHICAGO – Atrial fibrillation (AF) impacts about 33 million patients worldwide. Med-tech companies have responded to the challenge AF presents and have developed a number of ablation technologies to treat the disease. On Tuesday, a…

FacebookTwitterGoogle+Share

Short investor targets Pulse after run-up driven by ex-Pharmacyclics execs’ buy-in

By Stacy Lawrence, Staff Writer A tissue treatment device that can participate in the biotech-driven immuno-oncology fervor of the last few years may sound too good to be true. That’s precisely the case being made by long-short hedge fund Kerrisdale…

FacebookTwitterGoogle+Share

Front-wheel drive ‘capsule robot’ seeks colonoscopy outcome improvements

By Marie Powers, News Editor CHICAGO – An 18 millimeter capsule colonoscope, outfitted with an internal magnet and guided by an external magnet attached to a robotic arm, may represent the next generation of colonoscopy technology, according to findings presented…

FacebookTwitterGoogle+Share

Marketo